The Hutchinson-Gilford syndrome or progeria is a rare autosomal dominant 
syndrome characterized by premature aging and involvement of internal systems, 
such as the circulatory and locomotor. The diagnosis is essentially clinical and 
the manifestations become more evident from the first year of life. Long term 
outcome data from Progeria Research Foundation clinical trials have demonstrated 
an increase in survival in recent years. Even though new trials are ongoing, the 
recognition of this syndrome is essential to prevent cardiovascular and 
cerebrovascular complications. A patient, initially asymptomatic, who developed 
characteristic signs of the syndrome at the age of 6 months is reported. She was 
referred for evaluation only when she was two years and eleven months old. The 
diagnosis of Hutchinson-Gilford syndrome was suspected owing to clinical 
characteristics. The diagnosis was confirmed by genetic testing. A mutation 
c.1824C> T in exon 11 of the LMNA gene was detected. She was registered in the 
Progeria Research Foundation and was invited to participate in the weighing and 
supplementation program. She was included in the lonafarnib protocol study. This 
medication is a farnesyl transferase inhibitor that prevents the production of 
progerina and slows cardiovascular and neurological complications of the 
syndrome. This case highlights the importance of diagnosing progeria patients 
because they may be referred to the Progeria Research Foundation, which offers 
genetic screening and inclusion in clinical and therapeutic follow-up protocols 
without any costs. Progeria trials and research may also contribute to new drug 
developments related to prevention of aging and atherosclerosis in the near 
future.